Quest Diagnostics Incorporated

Quest Diagnostics Beats on EPS, Stock Down 3.97%

Quest Diagnostics reported an EPS that exceeded expectations, but the stock fell nearly 4% in reaction. The decline may reflect investor concerns or broader market trends, as no revenue figures were provided and no guidance was issued. The lack of additional context from management could also contribute to uncertainty among investors.